RxDoctor Payments Data

Indra Limbu, MD

Infectious Disease · Youngstown, OHNPI 1013946821

Payments from drug & device makers

$797in general payments, 2019–2025

Across 41 payments — averaging $19.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$299
  • AbbVie$115
  • La Jolla Pharmaceutical Company$57
  • Gilead$54
  • Shionogi Inc$44
  • Insmed, Inc.$43
  • plus $184 from 7 others

What the payments were for

  • Food & beverage$74694%
  • Education$516%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$797 in reported general payments places this provider in the 60th percentile of 308 infectious disease providers in Ohio.

See all infectious disease providers in Ohio

Medicare billing

Part B allowed, 2024
$174,717
Medicare patients
422
Services billed
2,132

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala355$1,363,213
GenvoyaElviteg/Cob/Emtri/Tenof Alafen84$354,928
TriumeqAbacavir/Dolutegravir/Lamivudi41$154,493
OdefseyEmtricitab/Rilpiviri/Tenof Ala36$129,389
TivicayDolutegravir Sodium42$119,356
IsentressRaltegravir Potassium48$89,119
DescovyEmtricitabine/Tenofov Alafenam39$82,550
CompleraEmtricita/Rilpivirine/Tenof Df18$65,773
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf11$51,849
TeflaroCeftaroline Fosamil Acetate14$42,645
Vancomycin Hcl105$30,931
Darunavir38$29,955
Etravirine25$26,391
ErtapenemErtapenem Sodium44$22,966
Daptomycin36$19,352

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$54$1,800,690478 claims
Viiv Healthcare CompanyTriumeq, Tivicay$43$273,84983 claims
MerckIsentress$299$89,11948 claims
AbbVieTeflaro$115$42,64514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 308 infectious disease providers in Ohio.

Other infectious disease in Youngstown

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →